The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection
Identifieur interne : 001C58 ( Istex/Corpus ); précédent : 001C57; suivant : 001C59The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection
Auteurs : S-Abdul Wahid Fadilah ; Kong-Chiew-Tong Norella ; Mohd-Said Shahril ; Raja-Sabudin Azma ; Chooi-Fun Leong ; Soon-Keng CheongSource :
- APLAR Journal of Rheumatology [ 0219-0494 ] ; 2006-09.
English descriptors
- Teeft :
- Aplar, Aplar journal, Autoantibody, Autoimmune, Autoimmune disease, Autoimmune phenomena, Case report, Clin rheumatol, Clinical manifestations, Dendritic, Dendritic cells, Discoid rash, Discontinuation, Erythematosus, Family history, Interferon, Interferon therapy, Kuala lumpur, Laboratory markers, Lupus, Malaysia, Numerous spherocytes, Peripheral blood, Platelet, Platelet count, Rheumatology, Serum transaminases, Systemic, Systemic lupus erythematosus, Universiti kebangsaan malaysia.
Abstract
Interferon‐alpha (IFN‐α) therapy has been associated with de novo development of systemic lupus erythematosus (SLE), and discontinuation of IFN‐α resulted in disease resolution in most patients. Recurrence of SLE in the absence of concomitant IFN‐α therapy has not been reported. We present here a woman who developed overt clinical manifestations of SLE one year after withdrawal of IFN‐α therapy for hepatitis C virus (HCV) infection. This report highlights the importance of long‐term follow‐up for the belated development of SLE in patients who have experienced IFN‐α induced autoimmune phenomena.
Url:
DOI: 10.1111/j.1479-8077.2006.00216.x
Links to Exploration step
ISTEX:BF7AA33A6CD07B339F907B8C6DD1D3610CA5FFA2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection</title><author><name sortKey="Wahid Fadilah, S Bdul" sort="Wahid Fadilah, S Bdul" uniqKey="Wahid Fadilah S" first="S-Abdul" last="Wahid Fadilah">S-Abdul Wahid Fadilah</name><affiliation><mods:affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medicine and</mods:affiliation></affiliation></author><author><name sortKey="Norella, Kong Hiew Ong" sort="Norella, Kong Hiew Ong" uniqKey="Norella K" first="Kong-Chiew-Tong" last="Norella">Kong-Chiew-Tong Norella</name><affiliation><mods:affiliation>Department of Medicine and</mods:affiliation></affiliation></author><author><name sortKey="Shahril, Mohd Aid" sort="Shahril, Mohd Aid" uniqKey="Shahril M" first="Mohd-Said" last="Shahril">Mohd-Said Shahril</name><affiliation><mods:affiliation>Department of Medicine and</mods:affiliation></affiliation></author><author><name sortKey="Azma, Raja Abudin" sort="Azma, Raja Abudin" uniqKey="Azma R" first="Raja-Sabudin" last="Azma">Raja-Sabudin Azma</name><affiliation><mods:affiliation>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</mods:affiliation></affiliation></author><author><name sortKey="Leong, Chooi Un" sort="Leong, Chooi Un" uniqKey="Leong C" first="Chooi-Fun" last="Leong">Chooi-Fun Leong</name><affiliation><mods:affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</mods:affiliation></affiliation></author><author><name sortKey="Cheong, Soon Eng" sort="Cheong, Soon Eng" uniqKey="Cheong S" first="Soon-Keng" last="Cheong">Soon-Keng Cheong</name><affiliation><mods:affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BF7AA33A6CD07B339F907B8C6DD1D3610CA5FFA2</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1479-8077.2006.00216.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-8B40753V-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001C58</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection</title><author><name sortKey="Wahid Fadilah, S Bdul" sort="Wahid Fadilah, S Bdul" uniqKey="Wahid Fadilah S" first="S-Abdul" last="Wahid Fadilah">S-Abdul Wahid Fadilah</name><affiliation><mods:affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medicine and</mods:affiliation></affiliation></author><author><name sortKey="Norella, Kong Hiew Ong" sort="Norella, Kong Hiew Ong" uniqKey="Norella K" first="Kong-Chiew-Tong" last="Norella">Kong-Chiew-Tong Norella</name><affiliation><mods:affiliation>Department of Medicine and</mods:affiliation></affiliation></author><author><name sortKey="Shahril, Mohd Aid" sort="Shahril, Mohd Aid" uniqKey="Shahril M" first="Mohd-Said" last="Shahril">Mohd-Said Shahril</name><affiliation><mods:affiliation>Department of Medicine and</mods:affiliation></affiliation></author><author><name sortKey="Azma, Raja Abudin" sort="Azma, Raja Abudin" uniqKey="Azma R" first="Raja-Sabudin" last="Azma">Raja-Sabudin Azma</name><affiliation><mods:affiliation>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</mods:affiliation></affiliation></author><author><name sortKey="Leong, Chooi Un" sort="Leong, Chooi Un" uniqKey="Leong C" first="Chooi-Fun" last="Leong">Chooi-Fun Leong</name><affiliation><mods:affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</mods:affiliation></affiliation></author><author><name sortKey="Cheong, Soon Eng" sort="Cheong, Soon Eng" uniqKey="Cheong S" first="Soon-Keng" last="Cheong">Soon-Keng Cheong</name><affiliation><mods:affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">APLAR Journal of Rheumatology</title><title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title><idno type="ISSN">0219-0494</idno><idno type="eISSN">1479-8077</idno><imprint><biblScope unit="vol">9</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="286">286</biblScope><biblScope unit="page" to="289">289</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-09">2006-09</date></imprint><idno type="ISSN">0219-0494</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0219-0494</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Aplar</term><term>Aplar journal</term><term>Autoantibody</term><term>Autoimmune</term><term>Autoimmune disease</term><term>Autoimmune phenomena</term><term>Case report</term><term>Clin rheumatol</term><term>Clinical manifestations</term><term>Dendritic</term><term>Dendritic cells</term><term>Discoid rash</term><term>Discontinuation</term><term>Erythematosus</term><term>Family history</term><term>Interferon</term><term>Interferon therapy</term><term>Kuala lumpur</term><term>Laboratory markers</term><term>Lupus</term><term>Malaysia</term><term>Numerous spherocytes</term><term>Peripheral blood</term><term>Platelet</term><term>Platelet count</term><term>Rheumatology</term><term>Serum transaminases</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Universiti kebangsaan malaysia</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interferon‐alpha (IFN‐α) therapy has been associated with de novo development of systemic lupus erythematosus (SLE), and discontinuation of IFN‐α resulted in disease resolution in most patients. Recurrence of SLE in the absence of concomitant IFN‐α therapy has not been reported. We present here a woman who developed overt clinical manifestations of SLE one year after withdrawal of IFN‐α therapy for hepatitis C virus (HCV) infection. This report highlights the importance of long‐term follow‐up for the belated development of SLE in patients who have experienced IFN‐α induced autoimmune phenomena.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>autoimmune</json:string><json:string>lupus</json:string><json:string>erythematosus</json:string><json:string>systemic lupus erythematosus</json:string><json:string>interferon</json:string><json:string>platelet</json:string><json:string>discontinuation</json:string><json:string>rheumatology</json:string><json:string>malaysia</json:string><json:string>dendritic</json:string><json:string>autoantibody</json:string><json:string>aplar</json:string><json:string>aplar journal</json:string><json:string>platelet count</json:string><json:string>peripheral blood</json:string><json:string>autoimmune disease</json:string><json:string>serum transaminases</json:string><json:string>case report</json:string><json:string>interferon therapy</json:string><json:string>autoimmune phenomena</json:string><json:string>family history</json:string><json:string>kuala lumpur</json:string><json:string>universiti kebangsaan malaysia</json:string><json:string>discoid rash</json:string><json:string>numerous spherocytes</json:string><json:string>laboratory markers</json:string><json:string>dendritic cells</json:string><json:string>clinical manifestations</json:string><json:string>clin rheumatol</json:string><json:string>systemic</json:string></teeft></keywords><author><json:item><name>S‐Abdul Wahid FADILAH</name><affiliations><json:string>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</json:string><json:string>Department of Medicine and</json:string></affiliations></json:item><json:item><name>Kong‐Chiew‐Tong NORELLA</name><affiliations><json:string>Department of Medicine and</json:string></affiliations></json:item><json:item><name>Mohd‐Said SHAHRIL</name><affiliations><json:string>Department of Medicine and</json:string></affiliations></json:item><json:item><name>Raja‐Sabudin AZMA</name><affiliations><json:string>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</json:string></affiliations></json:item><json:item><name>Chooi‐Fun LEONG</name><affiliations><json:string>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</json:string><json:string>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</json:string></affiliations></json:item><json:item><name>Soon‐Keng CHEONG</name><affiliations><json:string>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>autoimmune</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hepatitis C virus (HCV)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>interferon‐α (IFN‐α)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>side‐effects</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>systemic lupus erythematosus (SLE)</value></json:item></subject><articleId><json:string>APL216</json:string></articleId><arkIstex>ark:/67375/WNG-8B40753V-G</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>caseStudy</json:string></originalGenre><abstract>Interferon‐alpha (IFN‐α) therapy has been associated with de novo development of systemic lupus erythematosus (SLE), and discontinuation of IFN‐α resulted in disease resolution in most patients. Recurrence of SLE in the absence of concomitant IFN‐α therapy has not been reported. We present here a woman who developed overt clinical manifestations of SLE one year after withdrawal of IFN‐α therapy for hepatitis C virus (HCV) infection. This report highlights the importance of long‐term follow‐up for the belated development of SLE in patients who have experienced IFN‐α induced autoimmune phenomena.</abstract><qualityIndicators><score>4.829</score><pdfWordCount>1773</pdfWordCount><pdfCharCount>11856</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>4</pdfPageCount><pdfPageSize>595 x 779 pts</pdfPageSize><pdfWordsPerPage>443</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>88</abstractWordCount><abstractCharCount>601</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection</title><genre><json:string>case-report</json:string></genre><host><title>APLAR Journal of Rheumatology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1479-8077</json:string></doi><issn><json:string>0219-0494</json:string></issn><eissn><json:string>1479-8077</json:string></eissn><publisherId><json:string>APL</json:string></publisherId><volume>9</volume><issue>3</issue><pages><first>286</first><last>289</last><total>4</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2005</json:string><json:string>2006</json:string><json:string>2003</json:string></date><geogName></geogName><orgName><json:string>UKM</json:string><json:string>Department of Medicine</json:string><json:string>Malaysia Abstract Interferon</json:string><json:string>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia</json:string><json:string>Cancer Institute, Hospital Universiti Kebangsaan Malaysia</json:string><json:string>Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Asia Paci</json:string><json:string>Abdul Wahid</json:string><json:string>Fadilah</json:string></persName><placeName><json:string>Malaysia</json:string><json:string>Kuala Lumpur</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>W. Fadilah et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-8B40753V-G</json:string></ark><categories><wos></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - arthritis & rheumatology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1111/j.1479-8077.2006.00216.x</json:string></doi><id>BF7AA33A6CD07B339F907B8C6DD1D3610CA5FFA2</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-8B40753V-G/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-8B40753V-G/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-8B40753V-G/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection</title><title level="a" type="short">Interferon‐alpha therapy and SLE</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-09"></date></publicationStmt><notesStmt><note type="content-type" subtype="case-report" source="caseStudy" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-29919SZJ-6">case-report</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="case-report"><analytic><title level="a" type="main">The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection</title><title level="a" type="short">Interferon‐alpha therapy and SLE</title><author xml:id="author-0000"><persName><forename type="first">S‐Abdul</forename><surname>Wahid FADILAH</surname></persName><affiliation><orgName type="laboratory">Clinical Haematology and Stem Cell Transplantation Services</orgName><orgName type="institution">MAKNA‐HUKM Cancer Institute</orgName><orgName type="institution">Hospital Universiti Kebangsaan Malaysia (HUKM)</orgName></affiliation><affiliation><orgName type="division">Department of Medicine and</orgName></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Kong‐Chiew‐Tong</forename><surname>NORELLA</surname></persName><affiliation><orgName type="division">Department of Medicine and</orgName></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Mohd‐Said</forename><surname>SHAHRIL</surname></persName><affiliation><orgName type="division">Department of Medicine and</orgName></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Raja‐Sabudin</forename><surname>AZMA</surname></persName><affiliation><orgName type="department">Department of Pathology</orgName><orgName type="department">Faculty of Medicine</orgName><orgName type="institution">Universiti Kebangsaan Malaysia (UKM)</orgName><address><addrLine>Kuala Lumpur</addrLine><addrLine>Malaysia</addrLine><country key="MY" xml:lang="en">MALAYSIA</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Chooi‐Fun</forename><surname>LEONG</surname></persName><affiliation><orgName type="laboratory">Clinical Haematology and Stem Cell Transplantation Services</orgName><orgName type="institution">MAKNA‐HUKM Cancer Institute</orgName><orgName type="institution">Hospital Universiti Kebangsaan Malaysia (HUKM)</orgName></affiliation><affiliation><orgName type="department">Department of Pathology</orgName><orgName type="department">Faculty of Medicine</orgName><orgName type="institution">Universiti Kebangsaan Malaysia (UKM)</orgName><address><addrLine>Kuala Lumpur</addrLine><addrLine>Malaysia</addrLine><country key="MY" xml:lang="en">MALAYSIA</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Soon‐Keng</forename><surname>CHEONG</surname></persName><affiliation><orgName type="laboratory">Clinical Haematology and Stem Cell Transplantation Services</orgName><orgName type="institution">MAKNA‐HUKM Cancer Institute</orgName><orgName type="institution">Hospital Universiti Kebangsaan Malaysia (HUKM)</orgName></affiliation></author><idno type="istex">BF7AA33A6CD07B339F907B8C6DD1D3610CA5FFA2</idno><idno type="ark">ark:/67375/WNG-8B40753V-G</idno><idno type="DOI">10.1111/j.1479-8077.2006.00216.x</idno><idno type="unit">APL216</idno><idno type="toTypesetVersion">file:APL.APL216.pdf</idno></analytic><monogr><title level="j" type="main">APLAR Journal of Rheumatology</title><title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title><idno type="pISSN">0219-0494</idno><idno type="eISSN">1479-8077</idno><idno type="book-DOI">10.1111/(ISSN)1479-8077</idno><idno type="book-part-DOI">10.1111/apl.2006.9.issue-3</idno><idno type="product">APL</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">9</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="286">286</biblScope><biblScope unit="page" to="289">289</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-09"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>Interferon‐alpha (IFN‐α) therapy has been associated with de novo development of systemic lupus erythematosus (SLE), and discontinuation of IFN‐α resulted in disease resolution in most patients. Recurrence of SLE in the absence of concomitant IFN‐α therapy has not been reported. We present here a woman who developed overt clinical manifestations of SLE one year after withdrawal of IFN‐α therapy for hepatitis C virus (HCV) infection. This report highlights the importance of long‐term follow‐up for the belated development of SLE in patients who have experienced IFN‐α induced autoimmune phenomena.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">autoimmune</term><term xml:id="k2">hepatitis C virus (HCV)</term><term xml:id="k3">interferon‐α (IFN‐α)</term><term xml:id="k4">side‐effects</term><term xml:id="k5">systemic lupus erythematosus (SLE)</term></keywords><keywords rend="tocHeading1"><term>CASE REPORTS</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-8B40753V-G/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Asia</publisherName><publisherLoc>Melbourne, Australia</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1479-8077</doi><issn type="print">0219-0494</issn><issn type="electronic">1479-8077</issn><idGroup><id type="product" value="APL"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="APLAR JOURNAL OF RHEUMATOLOGY">APLAR Journal of Rheumatology</title></titleGroup></publicationMeta><publicationMeta level="part" position="09003"><doi origin="wiley">10.1111/apl.2006.9.issue-3</doi><numberingGroup><numbering type="journalVolume" number="9">9</numbering><numbering type="journalIssue" number="3">3</numbering></numberingGroup><coverDate startDate="2006-09">September 2006</coverDate></publicationMeta><publicationMeta level="unit" type="caseStudy" position="16" status="forIssue"><doi origin="wiley">10.1111/j.1479-8077.2006.00216.x</doi><idGroup><id type="unit" value="APL216"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="tocHeading1">CASE REPORTS</title></titleGroup><eventGroup><event type="firstOnline" date="2006-10-03"></event><event type="publishedOnlineFinalForm" date="2006-10-03"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-08"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="286">286</numbering><numbering type="pageLast" number="289">289</numbering></numberingGroup><correspondenceTo>
: Associate Professor Dr Fadilah S. Abdul Wahid, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia. E‐mail: <email>sfadilah@mail.hukm.ukm.my</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:APL.APL216.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="0"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="10"></count><count type="wordTotal" number="1623"></count></countGroup><titleGroup><title type="main">The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection</title><title type="shortAuthors">S.‐A.‐W. Fadilah <i>et al.</i></title><title type="short">Interferon‐alpha therapy and SLE</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1 #a2"><personName><givenNames>S‐Abdul</givenNames><familyName>Wahid FADILAH</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>Kong‐Chiew‐Tong</givenNames><familyName>NORELLA</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a2"><personName><givenNames>Mohd‐Said</givenNames><familyName>SHAHRIL</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a3"><personName><givenNames>Raja‐Sabudin</givenNames><familyName>AZMA</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a1 #a3"><personName><givenNames>Chooi‐Fun</givenNames><familyName>LEONG</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1"><personName><givenNames>Soon‐Keng</givenNames><familyName>CHEONG</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="MY"><unparsedAffiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</unparsedAffiliation></affiliation><affiliation xml:id="a2"><unparsedAffiliation>Department of Medicine and</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="MY"><unparsedAffiliation>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">autoimmune</keyword><keyword xml:id="k2">hepatitis C virus (HCV)</keyword><keyword xml:id="k3">interferon‐α (IFN‐α)</keyword><keyword xml:id="k4">side‐effects</keyword><keyword xml:id="k5">systemic lupus erythematosus (SLE)</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Interferon‐alpha (IFN‐α) therapy has been associated with de novo development of systemic lupus erythematosus (SLE), and discontinuation of IFN‐α resulted in disease resolution in most patients. Recurrence of SLE in the absence of concomitant IFN‐α therapy has not been reported. We present here a woman who developed overt clinical manifestations of SLE one year after withdrawal of IFN‐α therapy for hepatitis C virus (HCV) infection. This report highlights the importance of long‐term follow‐up for the belated development of SLE in patients who have experienced IFN‐α induced autoimmune phenomena.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Interferon‐alpha therapy and SLE</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection</title></titleInfo><name type="personal"><namePart type="given">S‐Abdul</namePart><namePart type="family">Wahid FADILAH</namePart><affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</affiliation><affiliation>Department of Medicine and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kong‐Chiew‐Tong</namePart><namePart type="family">NORELLA</namePart><affiliation>Department of Medicine and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mohd‐Said</namePart><namePart type="family">SHAHRIL</namePart><affiliation>Department of Medicine and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Raja‐Sabudin</namePart><namePart type="family">AZMA</namePart><affiliation>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chooi‐Fun</namePart><namePart type="family">LEONG</namePart><affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</affiliation><affiliation>Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Kuala Lumpur, Malaysia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Soon‐Keng</namePart><namePart type="family">CHEONG</namePart><affiliation>Clinical Haematology and Stem Cell Transplantation Services, MAKNA‐HUKM Cancer Institute, Hospital Universiti Kebangsaan Malaysia (HUKM),</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="case-report" displayLabel="caseStudy" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-29919SZJ-6">case-report</genre><originInfo><publisher>Blackwell Publishing Asia</publisher><place><placeTerm type="text">Melbourne, Australia</placeTerm></place><dateIssued encoding="w3cdtf">2006-09</dateIssued><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">1</extent><extent unit="tables">0</extent><extent unit="formulas">0</extent><extent unit="references">10</extent><extent unit="words">1623</extent></physicalDescription><abstract lang="en">Interferon‐alpha (IFN‐α) therapy has been associated with de novo development of systemic lupus erythematosus (SLE), and discontinuation of IFN‐α resulted in disease resolution in most patients. Recurrence of SLE in the absence of concomitant IFN‐α therapy has not been reported. We present here a woman who developed overt clinical manifestations of SLE one year after withdrawal of IFN‐α therapy for hepatitis C virus (HCV) infection. This report highlights the importance of long‐term follow‐up for the belated development of SLE in patients who have experienced IFN‐α induced autoimmune phenomena.</abstract><subject lang="en"><genre>keywords</genre><topic>autoimmune</topic><topic>hepatitis C virus (HCV)</topic><topic>interferon‐α (IFN‐α)</topic><topic>side‐effects</topic><topic>systemic lupus erythematosus (SLE)</topic></subject><relatedItem type="host"><titleInfo><title>APLAR Journal of Rheumatology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0219-0494</identifier><identifier type="eISSN">1479-8077</identifier><identifier type="DOI">10.1111/(ISSN)1479-8077</identifier><identifier type="PublisherID">APL</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>286</start><end>289</end><total>4</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Autoimmune aspects of cytokine and anticytokine therapies</title></titleInfo><name type="personal"><namePart type="given">I</namePart><namePart type="family">Krause</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Valesini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Scrivo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Shoenfeld</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krause I, Valesini G, Scrivo R, Shoenfeld Y (2003) Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 115, 390–7.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>115</number></detail><extent unit="pages"><start>390</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>115</number></detail><extent unit="pages"><start>390</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia</title></titleInfo><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Schilling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Kurzrock</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Kantarjian</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JU</namePart><namePart type="family">Gutterman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Talpaz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M (1991) Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68, 1536–7.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1536</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1536</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Systemic lupus erythematosus following interferon therapy</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Flores</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Olive</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Feliu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Tena</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Flores A, Olive A, Feliu E, Tena X (1994) Systemic lupus erythematosus following interferon therapy. Br J Rheumatol 33, 787.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>787</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Rheumatol</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>787</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Systemic lupus erythematosus with nephropathy after interferon‐α 2A therapy</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Yoshida</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Takeda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Koyama</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Morozumi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Oikawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yoshida A, Takeda A, Koyama K, Morozumi K, Oikawa T (1994) Systemic lupus erythematosus with nephropathy after interferon‐α 2A therapy. Clin Rheumatol 13, 382.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>382</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Rheumatol</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>382</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Systemic lupus erythematosus after interferon‐α therapy for chronic hepatitis C: a case report and review of the literature</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Fukuyama</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Kajiwara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Suzuki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Miyazaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Sadoshima</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Onoyama</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K (2000) Systemic lupus erythematosus after interferon‐α therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol 95, 310.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>310</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Gastroenterol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>310</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Systemic lupus erythematosus arising during interferon‐α therapy for cryoglobulinemic vasculitis associated with hepatitis C</title></titleInfo><name type="personal"><namePart type="given">TB</namePart><namePart type="family">Niewold</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WI</namePart><namePart type="family">Swedler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Niewold TB, Swedler WI (2005) Systemic lupus erythematosus arising during interferon‐α therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 24, 178–81.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>178</start><end>81</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Rheumatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>178</start><end>81</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Drug‐induced lupus</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Rubin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rubin R (2005) Drug‐induced lupus. Toxicology 209, 135–47.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>209</number></detail><extent unit="pages"><start>135</start><end>47</end></extent></part><relatedItem type="host"><titleInfo><title>Toxicology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>209</number></detail><extent unit="pages"><start>135</start><end>47</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Serum levels of interferons in patients with systemic lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Kanayama</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Negoro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Okamura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Takeda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Inoue</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T (1987) Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 70, 562–9.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>562</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Immunol</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>562</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Induction of dendritic cell differentiation by IFN‐α in systemic lupus erythematosus</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Blanco</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AK</namePart><namePart type="family">Palucka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Gill</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Pascual</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Banchereau</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN‐α in systemic lupus erythematosus. Science 294, 1540–3.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>1540</start><end>3</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>1540</start><end>3</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Effects of interferon on cell‐mediated immunity as manifested by delayed hypersensitivity and allograft rejection</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">DeMaeyer‐Guignard</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Interferon</title></titleInfo><originInfo><publisher>Elsevier</publisher></originInfo><part><date>1984</date><extent unit="pages"><start>131</start><end>45</end></extent></part></relatedItem></relatedItem><identifier type="istex">BF7AA33A6CD07B339F907B8C6DD1D3610CA5FFA2</identifier><identifier type="ark">ark:/67375/WNG-8B40753V-G</identifier><identifier type="DOI">10.1111/j.1479-8077.2006.00216.x</identifier><identifier type="ArticleID">APL216</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-8B40753V-G/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001C58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:BF7AA33A6CD07B339F907B8C6DD1D3610CA5FFA2
|texte= The development of systemic lupus erythematosus following interferon‐α therapy for hepatitis C infection
}}
| This area was generated with Dilib version V0.6.33. |  |